knowledge -WSS

knowledge

author：explore 2025-09-30 04:47:00 Page View：55224

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical devices makers are asking for forgiveness, not permission
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Texas board proposes rules on abortion law emergency exemption

MishaFriedman/GettyImagesTheTexasMedicalBoard,respondingtopressurefromthestateSupremeCourtandwidespr

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

CRISPR technology availability, affordability needs to be expanded

Fromleft,STAT'sJasonMast;JuliaVitarello,founder&CEOofMila’sMiracleFoundation;andFyodorUrnov,agen